• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Encysive Pharmaceuticals Announces Conference Call to Discuss Second Quarter 2005 Results

Posted on: Monday, 25 July 2005, 18:01 CDT

HOUSTON, July 25 /PRNewswire-FirstCall/ -- Encysive Pharmaceuticals will hold an investor conference call on Wednesday, August 3, 2005 at 4:30 p.m. ET to discuss its second quarter 2005 earnings results.

You may access the call either through the call-in number below or through the audio webcast. The access number for the call is:

Number: (612) 332-0820 Passcode: Encysive Pharmaceuticals

This call is being webcast and can be accessed via Encysive's web site at http://www.encysive.com/ .

A replay of the webcast will be available on the Company's web site through September 2, 2005. Additionally, a replay of the call will be available until August 10, 2005 at 11:59 p.m. ET. The call replay can be accessed by calling:

Number: (320) 365-3844 Access Code: 790853 About Encysive Pharmaceuticals

Encysive Pharmaceuticals Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of novel, synthetic, small molecule compounds to address unmet medical needs. Our research and development programs are predominantly focused on the treatment and prevention of interrelated diseases of the vascular endothelium and exploit our expertise in the area of the intravascular inflammatory process, referred to as the inflammatory cascade, and vascular diseases. We have successfully developed one FDA-approved drug, Argatroban, for the treatment of heparin-induced thrombocytopenia that is marketed by GlaxoSmithKline. The NDA for our lead drug candidate Thelin(TM) (sitaxsentan sodium), an endothelin A receptor antagonist for the treatment of PAH, is now under active review by the Cardio-Renal Division of the FDA. In addition, we have an earlier stage clinical product candidate in development, TBC3711, a next generation endothelin receptor antagonist. To learn more about Encysive Pharmaceuticals please visit our web site: http://www.encysive.com/ .

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Among those risks, trends and uncertainties are our estimate of the sufficiency of our existing capital resources, our ability to raise additional capital to fund cash requirements for future operations, timelines for initiating new clinical trials, planned announcements of clinical data, the possibility of obtaining regulatory approval, our ability to manufacture and sell any products, potential drug candidates, their potential therapeutic effect, market acceptance or our ability to earn a profit from sales or licenses of any drug candidate, our ability to discover new drugs in the future, and our ability to establish future collaborative arrangements. In particular, careful consideration should be given to cautionary statements made in the various reports Encysive, including as Texas Biotechnology Corporation, has filed with the Securities and Exchange Commission. Encysive undertakes no duty to update or revise these forward-looking statements.

Encysive Pharmaceuticals Inc.

CONTACT: investors, Ann Tanabe of Encysive Pharmaceuticals Inc.,+1-713-796-8822; or Marcy Strickler of The Trout Group, +1-212-477-9007,ext. 27; or media, Dan Budwick of BMC Communications, +1-212-477-9007,ext. 14, both for Encysive Pharmaceuticals Inc.

Web site: http://www.encysive.com/

Source: PRNewswire-FirstCall

More News in this Category